Determining Prognostic Immune Markers in Patients With Ovarian Cancer
NCT ID: NCT03862677
Last Updated: 2021-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2020-08-15
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Immune Landscape of Epithelial Ovarian Cancer
NCT05984875
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01295489
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
NCT04675320
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NCT06084195
Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors
NCT05640024
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with (suspicion of) primary EOC
No intervention
Observational study, no intervention
Patients with recurrent EOC
No intervention
Observational study, no intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Observational study, no intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years.
* WHO performance status 0-2.
* Accessible for treatment and follow-up.
* Written informed consent.
Exclusion Criteria
* Any known severe infection like HIV, hepatitis A, B and C.
* Receiving immune suppressive treatment.
* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leiden University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
J.R. Kroep
Principal Investigator MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Judith R Kroep, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Leiden University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leiden University Medical Center
Leiden, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Judith R Kroep, MD PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL66869.058.19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.